The use of the PARP inhibitor olaparib (Lynparza) for 1 year after receiving standard chemotherapy in the neoadjuvant or the adjuvant setting significantly improved invasive disease-free survival in patients with high-risk, early-stage, HER2-negative breast cancer and BRCA1 or BRCA2 mutations, according to results presented at the American Society of Clinical Oncology 2021 virtual annual meeting. Read More ›

In patients receiving treatment with CDK4/6 inhibitors, levels of neutralizing antibodies post-vaccination were similar to those in matched healthy controls. Read More ›

Although CDK4/6 inhibitors in the treatment of patients with hormone receptor–positive/HER2-negative advanced breast cancer improve progression-free survival, this therapeutic intervention is also associated with higher rates of adverse events. Read More ›

To ensure the correct use of healthcare services, it is critical to invest in training nursing professionals who must educate patients on the timely recognition and management of complications. Read More ›

Research suggests that, when used in routine clinical practice in first or subsequent lines of treatment, ribociclib and palbociclib resulted in toxicity and efficacy outcomes in agreement with pivotal trial expectations. Read More ›

A small study suggests that in select patients with long-lasting disease stabilization, elective discontinuation of CDK4/6 inhibitors is feasible. Read More ›

A large retrospective cohort population-based study demonstrated a disproportionate elevation of breast cancer–specific and all-cause mortality among African American women. Read More ›

For the treatment of patients with HR-positive/HER2-negative metastatic breast cancer, targeting CDK4/6 represents a novel, effective, and safe therapeutic approach in combination with hormone therapy. Read More ›

Page 1 of 23

Subscribe to The Oncology Nurse-APN/PA

To sign up for our newsletter or print publications, enter your contact information below.

I'd like to receive: